Provention Bio, Inc. Loss Submission Form

See If You Qualify For Monetary Reward

Enter your details and we will calculate your loss for you

Submit Transaction Detail Now (Optional)

- OR -

    This submission does not create an attorney-client relationship. We will keep you up to date with this investigation, and should this investigation evolve, we will contact you to discuss whether to establish an attorney client relationship at no cost to you.

    Review Our Privacy Policy

    FAX: 212-363-7171

    Levi & Korsinsky, LLP announces that a PRVB class action lawsuit has been filed on behalf of investors who purchased Provention Bio, Inc. (PRVB) securities between November 2, 2020 and April 8, 2021. For more on the PRVB Lawsuit please contact us today.

    According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA’s approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

    If you suffered a loss in you have until July 20, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.